Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Bioceros B.V. announces change of ownership

Utrecht, The Netherlands, February 17th, 2011 - Bioceros B.V. announces that it has successfully realized a change of ownership. This is the result of the purchase of the outstanding shares owned by Forbion, Thuja Capital and Biogeneration Ventures by existing shareholders and the management team.

Bioceros’ CEO, Dr. Bram Bout comments: “The financial round of 2008, which was led by Thuja Capital and Biogeneration Ventures, has allowed us to build a strong, independent service business and to lay the foundation for a product pipeline. We are therefore pleased and proud that we can offer our investors this exit. Bioceros will further grow its service business by expanding its technology platform and spin out its early-stage products in a separate legal entity.”

Dr. Mark de Boer (chairman) and Dr. Oscar Schoots, MBA, will remain members of the Supervisory Board of Bioceros.

About Bioceros.

Bioceros is a biotech company focusing on pre-clinical development of protein products, with an emphasis on monoclonal antibodies. Bioceros’ technology platform covers early pre-clinical development of monoclonal antibodies, including generation of monoclonal antibodies in mice, making high protein producing CHO and PER.C6® cell lines, assay development and pre-clinical manufacturing at 20L scale. This is all Quality Controlled, using state of the art serum-free culture media, such that the generated cell lines can be used for GMP manufacturing. Bioceros is preferred vendor of DSM Biologics and Crucell for PER.C6® cell line generation services.
Bioceros uses this technology platform to offer services to the industry and academia, and to develop its own pipeline of monoclonal antibody products.

Bioceros is located in Utrecht, the Netherlands. For more information, please visit or contact:

Remco M. Brandt
Bioceros BV
Yalelaan 46
The Netherlands

Phone: +31(0) 30-253 7910
Cell: +31(0) 6-1012 7709
Fax: +31(0) 30-253 2288

Publisher Contact Information:

+31(0) 30-253 7910

Company profile of Bioceros (acquired by Epirus)
Past press releases of Bioceros (acquired by Epirus).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Oct 4€16.0MBiopharmaceuticals
Oct 1€12.5MWireless applications
Oct 1€3.1MBiotechnology
Oct 1€10.0MInternet services
Sep 30€25.0MSoftware development
Sep 29€7.1MComputer hardware
Sep 29€12.0MBiopharmaceuticals

For information on Europe's most extensive database on technology funding click here!


BIO-Europe 2015
November 2 - 4, 2015

November 10 - 11, 2015

Press Releases

Oct 6
versasec triples government security business

Sep 30
BioRegio STERN Management
tübingen-based start-up atriva therapeutics gmbh develops innovativ...

Sep 29
Magic Event
with 1.5 million euros in hand, is looking to attrac...

Sep 29
swarm64 as raises up to eur7.1m from alliance venture, target partn...

Sep 29
Cristal Therapeutics (formerly Cristal Delivery)
cristal therapeutics starts clinical phase i trial with nanomedicin...

About usContact usLegal Information
Copyright © 1999-2015
Emerging Technology Research Europe Inc. All rights reserved.